2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1679 Mutation burden and comutational architecture refine prognostic stratification in acute myeloid leukemia harboring secondarytype mutations: Insights from a multicenter retrospective cohort

Jieni Yu, MD, Yu Zhu, MD2, Ying Lu3, Shanhao Tang, MD4, Hongming Zhu5, Jie Jin, MD6, Huafeng Wang, MD7
1 Shaoxing People's Hospital, Shaoxing, Zhejiang, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
2 Jiangsu Province Hospital,The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
3 The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China
4 The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
5 National Research Center for Translational Medicine at Shanghai, Shanghai, Shanghai, China, Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, Shanghai Institute of Hematology, Shanghai, Shanghai, China, State Key Laboratory of Medical Genomics, Shanghai, Shanghai, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China

Background: 

Secondary-type mutations (STMs) are integral to contemporary AML classification, yet current risk stratification does not fully capture outcome heterogeneity within STM-positive AML. We evaluated treatment outcomes and the prognostic relevance of STM burden, functional class, individual gene mutations, and co-mutational architecture in a multicenter retrospective cohort.

Methods: 

We analyzed 978 adults with AML excluding acute promyelocytic leukemia, harboring at least one of eight predefined STMs (ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2) from five centers participating in the East China Leukemia Alliance. Frontline therapy was categorized as intensive chemotherapy (IC), venetoclax plus IC (Ven+IC), less intensive therapy (LIT), or venetoclax plus LIT (Ven+LIT). Cycle 1 response and overall survival (OS) were evaluable in 825 and 973 patients, respectively. STM burden was assessed as a single STM versus multiple STMs and as 1, 2, or ≥3 STMs; functional class was categorized as splicing-only, non-splicing-only, or mixed. Gene-specific OS associations were evaluated using Cox models. Pairwise OS comparisons used log-rank tests with Holm adjustment. All 28 STM pairs were assessed for co occurrence using observed to expected (O/E) ratios and for prognostic interaction using multiplicative Cox terms, with Benjamini–Hochberg correction. FDR-significant pairs and the most frequent pair were further evaluated using four-group survival analyses and multivariable Cox models adjusted for age, sex, white blood cell count, TP53 and NPM1 mutation status, frontline treatment, and additional STM burden, stratified by center.

Results: 

Patient characteristics and STM prevalence

The study cohort comprised 978 patients with a median age of 62 years (IQR, 51–69); 57.8% were male, and 85.1% had de novo AML. ASXL1 was the predominant STM (43.4%), followed by SRSF2 (20.6%) and BCOR (19.6%); 262 patients (26.8%) carried ≥2 STMs.

Response and survival by frontline therapy

Cycle 1 composite complete remission (CRc) rates were 60.0% for Ven+IC, 67.4% for IC, 67.3% for Ven+LIT, and 46.8% for LIT (P<0.001). Among measurable residual disease (MRD)-evaluable CRc responders, MRD-negativity rates were 85.1%, 61.4%, 81.9%, and 66.7%, respectively (p<0.001). At a median follow-up of 18.2 months, 2-year OS was similar between Ven+IC and IC (77.9% vs 75.3%; p=0.869) and between Ven+LIT and LIT (55.8% vs 55.8%; p=0.869), whereas observed OS was higher in each intensive-treatment group than in either less-intensive-treatment group (all P<0.001).

Prognostic impact of STM burden, functional class, and individual genes

Multiple STMs were associated with inferior OS (P<0.001), with a stepwise decline across 1, 2, and ≥3 STMs (P<0.001). OS also differed by functional class, with non-splicing-only STMs showing the most favorable survival (P<0.001). SRSF2 was associated with inferior OS (HR, 1.46; p=0.008), whereas ASXL1 showed a nonsignificant trend toward inferior OS (HR, 1.25; p=0.060); EZH2 alone was not associated with OS (HR, 1.01; p=0.939).

Co-mutational interaction analysis

ASXL1/SRSF2 was the most frequent (n=86) but demonstrated neither significant co-occurrence (O/E, 0.99; q=0.906) nor prognostic interaction (interaction HR, 0.90; q=0.992). FDR-significant adverse interactions were identified for ASXL1×EZH2 (n=39; interaction HR, 3.21; q=0.036) and ASXL1×STAG2 (n=44; interaction HR, 3.01; q=0.047); the ASXL1/EZH2 pair was not co-enriched (O/E, 0.81; q=0.086). Among patients with neither mutation, ASXL1-only, EZH2-only, or both mutations, the double-mutant group had the poorest OS (log-rank p=0.001). After multivariable adjustment, the ASXL1×EZH2 interaction remained significant (interaction HR, 2.82; p=0.008), whereas the ASXL1×STAG2 interaction did not (interaction HR, 1.62; p=0.232).

Conclusions: 

STM positive AML exhibits substantial heterogeneity in treatment response and survival. Increasing STM burden was associated with progressively inferior OS, whereas non splicing only STMs identified a more favorable subgroup. Co mutation frequency did not reliably predict prognostic interaction. Of the two FDR significant adverse pairs, only the ASXL1×EZH2 interaction remained significant after multivariable adjustment, despite no adverse association for EZH2 alone. STM burden and co mutational architecture may provide complementary prognostic information and warrant validation in independent cohorts.

Huafeng Wang, MD: No relevant conflicts of interest to declare.